Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.57 |
| ▸ | PIM1 | P11309 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.54 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | CLK2 | P49760 | 3/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.47 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901930 | 0.82 | ROCK2 (0.67) | ROCK2PIM1GSK3BCLK4STK17A | |
| SCHEMBL3670760 | 0.82 | ROCK2 (0.67) | ROCK2PIM1GSK3BCLK4STK17A | |
| SCHEMBL3669097 | 0.78 | ROCK2 (0.65) | ROCK2PIM1GSK3BCLK4STK17A | |
| SCHEMBL4083317 | 0.77 | NPC1 (0.52) | HDAC4USP30SCD5HDAC6NPC1 | |
| SCHEMBL312320 | 0.77 | ROCK2 (0.68) | ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL21536314 | 0.77 | RAB9A (0.64) | HDAC4USP30SCD5NPC1RAB9A | |
| SCHEMBL4262768 | 0.75 | GPR119 (0.51) | ROCK2CLK4STK17ADYRK1ACLK2 | |
| SCHEMBL3668427 | 0.74 | ROCK2 (1.00) | ROCK2PIM1GSK3BCLK4STK17A | |
| SCHEMBL9952336 | 0.74 | FASN (0.52) | ROCK2PIK3CDMEN1KMT2A | |
| SCHEMBL14514349 | 0.74 | ROCK2 (0.63) | ROCK2ROCK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | ROCK2 858/4885PIM1 616/4885GSK3B 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.